- Shifting to value-based care improves patient outcomes and cost-effective provider efficiency.
- Adageis’ ProActive Care shifts focus from reactive treatment to preventive, patient-centered care, with AI-driven analytics identifying high-risk patients and addressing care gaps.
- Patients receive more personalized, effective treatment, rather than a volume treatment driven approach.
- Better patient outcomes lead to reduced hospitalizations and cost savings, while increased cost monitoring and efficiency for providers supports increased revenue and net income potential.
For many patients, the American healthcare system often feels rushed, transactional and fragmented. Doctors have limited time, and treatment decisions can be driven by billing structures rather than patient well-being.
The traditional fee-for-service model rewards volume—more tests, more procedures, more appointments—without necessarily improving patient outcomes. This system can lead to unnecessary or ineffective treatments, frustrating patients and increasing provider administrative burdens. A shift toward value…
NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
